Skip to content
Cardiff Oncology
  • FOR INVESTORS
    • Stock Quote
    • Corporate Presentation
    • News & Events
    • SEC Filings
    • Governance
    • Shareholder Services
  • Onvansertib
  • Pipeline
  • Clinical Programs
    • ONSEMBLE mCRC
    • mCRC
    • mPDAC
    • Scientific Presentations
  • Leadership
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Contact Us
  • For Investors
    • Stock Quote
    • Corporate Presentation
    • News & Events
    • SEC Filings
    • Governance
    • Shareholder Services

Category: Uncategorized

Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer

Posted on May 14, 2021January 10, 2022 by nathan
Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer
Cardiff logo

11055 Flintkote Ave.
San Diego, CA 92121

858-952-7570

  • LinkedIn
  • Twitter
  • Facebook
  • Contact Us
  • Terms Of Use
  • Privacy Policy

© Cardiff Oncology, Inc. All rights reserved. Site Design